Concepedia

Minwei Ye

MY

Statistics

Publications

19

Citations

1.4K

H-Index

17

Active since

2008

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

AstraZeneca (Brazil)

AstraZeneca (South Korea)

Blueprint Medicines (United States)

Minwei Ye is an author at AstraZeneca (United States) specializing in pharmacology, jak inhibitors, and drug discovery.

Publications per year

2008–2025

19

Publications

19

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

Michael Hedvat, Dennis Huszar, Andreas Herrmann et al. · Cancer Cell · 2009 · 529 citations · Full text

, , +9

Differentially Private Empirical Risk Minimization Revisited: Faster and\n More General

Di Wang, Minwei Ye, Jinhui Xu · arXiv (Cornell University) · 2018 · 142 citations · Full text

, , +15

Discovery of 5-Chloro-<i>N</i><sup>2</sup>-[(1<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i><sup>4</sup>-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway

Stephanos Ioannidis, Michelle L. Lamb, Tao Wang et al. · Journal of Medicinal Chemistry · 2010 · 123 citations · Full text

, , +15

Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunity

Alexandra Borodovsky, Christine M. Barbon, Yanjun Wang et al. · Journal for ImmunoTherapy of Cancer · 2020 · 102 citations · Full text

, , +17

Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2

Joseph M. Gozgit, Geraldine Bebernitz, Pankaj Patil et al. · Journal of Biological Chemistry · 2008 · 101 citations · Full text

, , +13

1–5 of 19